Kurt Gustafson Biography and Net Worth

Director of Xencor

Kurt A. Gustafson joined our Board in July 2014. Mr. Gustafson has more than 25 years of diverse experience in corporate finance, with 20 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industry organizations. Mr. Gustafson has served as Chief Financial Officer of OmniAb Inc., a publicly traded biopharmaceutical company, since March 2022. From June 2013 to March 2022, he served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and from April 2009 to June 2013, he served as Chief Financial Officer at Halozyme Therapeutics, Inc. (“Halozyme”), a publicly traded biopharmaceutical company. Before Halozyme, Mr. Gustafson worked at Amgen for over 18 years holding various positions in finance including Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson holds a Bachelor of Arts degree in accounting from North Park University in Chicago and an M.B.A. from University of California, Los Angeles. We believe Mr. Gustafson’s experience in biotechnology company leadership and finance and his educational background qualify him to serve on our Board.

What is Kurt A. Gustafson's net worth?: The estimated net worth of Kurt A. Gustafson is at least $1.92 million as of April 1st, 2025. Mr. Gustafson owns 217,492 shares of Xencor stock worth more than $1,920,454 as of May 12th. This net worth evaluation does not reflect any other investments that Mr. Gustafson may own. Learn More about Kurt A. Gustafson's net worth.
How do I contact Kurt A. Gustafson?: The corporate mailing address for Mr. Gustafson and other Xencor executives is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. Xencor can also be reached via phone at (626) 305-5900 and via email at investors@xencor.com. Learn More on Kurt A. Gustafson's contact information.
Has Kurt A. Gustafson been buying or selling shares of Xencor?: Kurt A. Gustafson has not been actively trading shares of Xencor during the past quarter. Most recently, Kurt A. Gustafson sold 14,000 shares of the business's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $23.18, for a transaction totalling $324,520.00. Following the completion of the sale, the director now directly owns 6,007 shares of the company's stock, valued at $139,242.26. Learn More on Kurt A. Gustafson's trading history.
Who are Xencor's active insiders?: Xencor's insider roster includes Bassil Dahiyat (CEO), John Desjarlais (Executive Vice President, Research & Chief Scientific Officer), Celia Eckert (Senior Vice President, General Counsel and Corporate Secretary), Kurt Gustafson (Director), Alan Montgomery (Director), and Allen Yang (CMO). Learn More on Xencor's active insiders.
Are insiders buying or selling shares of Xencor?: In the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 176,995 shares worth more than $3,994,070.52. The most recent insider tranaction occured on May, 2nd when EVP Nancy Valente sold 4,616 shares worth more than $50,914.48. Insiders at Xencor own 4.8% of the company. Learn More about insider trades at Xencor.
Information on this page was last updated on 5/2/2025.

Kurt A. Gustafson Insider Trading History at Xencor

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/6/2024	Sell	14,000	$23.18	$324,520.00	6,007

Kurt A. Gustafson Buying and Selling Activity at Xencor

Xencor Company Overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Today's Range

Now: $8.77

$8.62

$9.18

50 Day Range

MA: $10.73

$7.67

$13.90

2 Week Range

Now: $8.77

$7.16

$27.24

Volume

822,244 shs

Average Volume

641,916 shs

Market Capitalization

$624.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99